Sollis Therapeutics, Inc., an Ohio-based interventional pain therapeutics company, announced that the first patient was enrolled in the RePRIEVE-CM trial, a Phase 3 clinical trial evaluating the efficacy and safety of the extended release non-opioid, non-steroid clonidine micropellet for the treatment of sciatica pain.
Sollis Therapeutics’ CEO, Gregory Fiore, MD, will join the panel of speakers on November 14, 2018 at the BioOhio conference. This conference will highlight innovations in neuroscience research and technologies that are addressing the opioid crisis. This event will also feature an Alternatives to Opioids Tech Showcase.
Neurosurgeon Dr. Ali Rezai says he didn’t inspire Gov. John Kasich’s decision to earmark $20 million from Ohio Third Frontier for commercializing technology to fight opioid addiction. But he does have a startup primed to compete for funds.
The first step in the state’s effort to find new innovations to fight the opiate crisis has been taken. Ten million was just awarded to seven projects in the works to become reality. One from a company here in Columbus,
Neurotechnology Innovations Translator (NIT), an Ohio-based company focused on advancing the development and commercialization of innovative neurotechnology solutions, announced the funding of up to $50 million for its second portfolio company, Sollis Therapeutics (Sollis).
NEW YORK and COLUMBUS, Ohio, April 12, 2018 /PRNewswire/ — Deerfield Management and Sollis Therapeutics today announced a Deerfield-led investment of up to $50 million in Sollis Therapeutics. The investment will support the development of an innovative non-opioid and non-steroid
Every day, more than 90 Americans die from opioid overdoses—prescription pain relievers, heroin, and synthetics such as fentanyl. The number has quadrupled since 1999, and the problem has permeated and devastated communities, schools and families. Ohio knows the ravaging effects of this
A new pain pellet that scientists are developing in Columbus is about half the size of a grain of rice, but researchers say it delivers a big dose of relief that could one day help fight the opioid epidemic.
The Neurotechnology Innovations Translator LLC turned to pharmaceutical experts on both coasts, asking them to evaluate the promise of pain-fighting technology that reduces the need for opioid prescriptions. They both were so excited about it they joined as the startup’s